- Home
- Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.
The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.
This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.
Disclosure
In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.
This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.
Terms & Conditions
Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA) for 1 hour of external CPD credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Learning Objectives
- Understand the latest ARNI data in HFpEF and HFrEF
- Understand how emerging data relates to current practice in Malaysia
- Apply current understanding of ARNI therapy in appropriate heart failure patients
Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)
Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action
Duration:
Speakers: James L Januzzi (Massachusetts General Hospital, US) Akshay S Desai (Brigham and Women’s Hospital, Boston, MA, US) Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)
Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)
Clinical questions on ARNI therapy – Chapter 5: Summary
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Related Courses
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
- Not accredited
Published:
Learning objectives
- Recall guideline recommendations for the use of NT-proBNP in heart failure
- Describe current practices in heart failure diagnosis and the impact on treatment outcomes
- Develop an optimised approach to the timely diagnosis and management of heart failure
- 2.00
Published:
Learning objectives
- Recall clinical evidence and guidelines for the management of CKD patients without diabetes
- Describe current gaps and barriers in evidence-based management for CKD without diabetes
- Apply evidence based-management strategies to a case study
- Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists